Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 6

Neoteric Approach of Fluoxetine Laden Orodispersible Film for Non-compliant Pediatric Patients of Selective Mutism and Obsessivecompulsive Disorder

Seçici Mutizm ve Obsesif Kompulsif Bozukluğu olan Uyumsuz Pediatrik Hastalar için Fluoksetin Ladenin Ağızda Dağılan Filmi için Yeni Yaklaşım

Pages
683–694
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, the perspective of using fluoxetine ODFs for individualized pharmacotherapy to ameliorate the compliance issues in selective mutism and OCD pediatric patients can be considered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The objective of this research was to fabricate, characterize, and optimize fluoxetine laden orodispersible film (ODF), in enhancing dosage forms options for the pediatric population suffering from incapacitating psychotic disorders of selective mutism and obsessive-compulsive disorder, which will be ultimately beneficial in enhancing compliance factor and the quality of pharmacotherapy.
📊
Key Findings & Data:Materials and Methods: Solvent casting technique was used to formulate the ODF formed by natural hydrophilic polymers matrix of hydroxypropyl methylcellulose E15 and pullulan.
💡
Conclusion & Impact:Therefore, the perspective of using fluoxetine ODFs for individualized pharmacotherapy to ameliorate the compliance issues in selective mutism and OCD pediatric patients can be considered.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The objective of this research was to fabricate, characterize, and optimize fluoxetine laden orodispersible film (ODF), in enhancing dosage forms options for the pediatric population suffering from incapacitating psychotic disorders of selective mutism and obsessive-compulsive disorder, which will be ultimately beneficial in enhancing compliance factor and the quality of pharmacotherapy. Materials and Methods: Solvent casting technique was used to formulate the ODF formed by natural hydrophilic polymers matrix of hydroxypropyl methylcellulose E15 and pullulan. Propylene glycol as plasticizing agent imparted satisfactory tenacity and flexibility to ODFs. Fourier transform infrared spectroscopy studies were performed to investigate any potential compatibility, and the results revealed no potential interaction between fluoxetine and excipients. Developed ODFs were evaluated for physicochemical properties, content uniformity, in vitro disintegration time, and in vitro dissolution time studies. Results: The experimental data suggested that different polymer concentrations had a complex effect on content uniformity, in vitro disintegration time, and cumulative percentage drug release from the ODFs. TF7 was the most optimized formulation with a disintegration time of 10.66 sec and 99.37% drug release within 3 min. Additionally, the most optimized fluoxetine ODF was submitted to a Universal Testing Machine for tensile strength and percentage elongation determination. It was also further evaluated by thermogravimetric analysis, scanning electron microscopy and X-ray diffraction. Conclusion: Fluoxetine ODFs of good pharmaceutical quality can be prepared on a small scale. Therefore, the perspective of using fluoxetine ODFs for individualized pharmacotherapy to ameliorate the compliance issues in selective mutism and OCD pediatric patients can be considered.

Özet

Amaç: Bu araştırmanın amacı, seçici mutizm ve obsesif-kompulsif bozukluğu gibi inkapasite edici psikotik bozuklukları olan pediatrik popülasyon için sonuçta uyum faktörünü ve farmakoterapinin kalitesini artırmada yararlı olabilecek fluoksetin yüklü ağızda dağılan filmi (ODF) imal etmek, karakterize etmek ve optimize etmektir. Gereç ve Yöntemler: Hidroksipropil metil selüloz E15 ve pulluhanın doğal hidrofilik polimer matrisi tarafından oluşturulan ODF’yi formüle etmek için çözücü döküm tekniği kullanılmıştır. Plastikleştirici madde olarak propilen glikol, ODF’lere tatmin edici dayanıklılık ve esneklik kazandırmıştır. Olası uyumluluğu araştırmak için fourier dönüşümü kızılötesi spektroskopisi çalışmaları yapılmış ve sonuçlar fluoksetin ile eksipiyanlar arasında potansiyel bir etkileşim olmadığını ortaya koymuştur. Geliştirilen ODF’ler fizikokimyasal özellikler, içerik homojenliği, in vitro parçalanma süresi ve in vitro çözünme süresi çalışmaları için değerlendirilmiştir. Bulgular: Deneysel veriler farklı polimer konsantrasyonlarının, içerik tekdüzeliği, in vitro parçalanma süresi ve ODF’lerden kümülatif ilaç salımı yüzdesi üzerinde karmaşık bir etkiye sahip olduğunu göstermiştir. TF7, 10,66 saniyelik dağılma süresi ve 3 dakika içinde %99,37 ilaç salımı ile en optimize edilmiş formülasyon olarak belirlenmiştir. Ek olarak, en optimize fluoksetin ODF, gerilme mukavemeti ve uzama yüzdesi belirlemesi için bir Evrensel Test Makinesi’ne gönderilmiştir. Ayrıca termogravimetrik analiz, taramalı elektron mikroskobu ve X-ışını kırınımı ile de değerlendirilmiştir. Sonuç: İyi farmasötik kalitede fluoksetin ODF’leri küçük ölçekte hazırlanabilir. Bu nedenle, seçici mutizm ve OKB pediatrik hastalarda uyum sorunlarını iyileştirmek için bireyselleştirilmiş farmakoterapi için fluoksetin ODF’lerin kullanılması perspektifi düşünülebilir.

🔖

Cite This Article

DAD, H. A., SHABBIR, A. S., ALI, S., MAHMOOD, T. (2022). Neoteric Approach of Fluoxetine Laden Orodispersible Film for Non-compliant Pediatric Patients of Selective Mutism and Obsessivecompulsive Disorder. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 6, 683–694. https://ajindex.com/articles/613664

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Strickley RG, Iwata Q, Wu S, Dahl TC. Pediatric drugs-a review of commercially available oral formulations. J Pharm Sci. 2008;97:1731- 1774. 2. van Riet-Nales DA, Schobben AF, Vromans H, Egberts TC, Rademaker CM. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Childh. 2016;101:662-669
  2. Senta‐Loys Z, Bourgeois S, Pailler‐Mattei C, Agusti G, Briançon S, Fessi, H. Formulation of orodispersible films for paediatric therapy: investigation of feasibility and stability for tetrabenazine as drug model. J Pharm Pharmacol. 2017;69:582-592
  3. Dahiya M, Saha S, Shahiwala AF. A review on mouth dissolving films. Curr Drug Deliv. 2009;6:469-476
  4. Zarafshan H, Mohammadi MR, Salmanian M. prevalence of anxiety disorders among children and adolescents in Iran: a systematic review. Iran J Psychiatry. 2015;10:1-7
  5. Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry (Edgmont). 2010;7:23-31
  6. Stein DJ, Craske MA, Friedman MJ, Phillips KA. Anxiety disorders, obsessive-compulsive and related disorders, trauma- and stressorrelated disorders, and dissociative disorders in DSM-5. Am J Psychiatry. 2014;171:611-613
  7. Capozzi F, Manti F, Di Trani M, Romani M, Vigliante M, Sogos C. Children’s and parent’s psychological profiles in selective mutism and generalized anxiety disorder: a clinical study. Eur Child Adolesc Psychiatry. 2018;27:775-783
  8. Barterian JA, Sanchez JM, Magen J, Siroky AK, Mash BL, Carlson JS. An examination of fluoxetine for the treatment of selective mutism using a nonconcurrent multiple-baseline single-case design across 5 cases. J Psychiatr Pract. 2018;24:2-14
  9. Alaghband-Rad J, Hakimshooshtary M. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry. 2009;18:131-135
  10. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin SH, Sallee FR, Schmidt AB, Simpson HB. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1431-1438
  11. Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32:149-157
  12. Carlson JS, Mitchell AD, Segool N. The current state of empirical support for the pharmacolog